Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Classic Hodgkin Lymphoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT04510636
What this trial is testing

Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma

Who this might be right for
Classical Hodgkin LymphomaRelapsed CancerRefractory Cancer
University Health Network, Toronto 40
Testing effectiveness (Phase 2)UnknownNCT03077828
What this trial is testing

Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Who this might be right for
Lymphocyte-Rich Classical Hodgkin LymphomaRecurrent Lymphocyte-Depleted Classical Hodgkin LymphomaRecurrent Mixed Cellularity Classical Hodgkin Lymphoma+4 more
Northwestern University 43
Testing effectiveness (Phase 2)Active Not RecruitingNCT04938232
What this trial is testing

Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL

Who this might be right for
Hodgkin LymphomaRelapsed Hodgkin's Disease, AdultRefractory Hodgkin Lymphoma
Dana-Farber Cancer Institute 13
Large-scale testing (Phase 3)Not Yet RecruitingNCT07572123
What this trial is testing

Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma

Who this might be right for
Recurrent Classic Hodgkin LymphomaRefractory Classic Hodgkin Lymphoma
National Cancer Institute (NCI) 374
Testing effectiveness (Phase 2)Active Not RecruitingNCT01896999
What this trial is testing

Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Who this might be right for
Recurrent Classic Hodgkin LymphomaRefractory Classic Hodgkin Lymphoma
National Cancer Institute (NCI) 146
Testing effectiveness (Phase 2)Study completedNCT02164500
What this trial is testing

JAK-inhibition in Recurrent Classical Hodgkin Lymphoma

Who this might be right for
Recurrent Classical Hodgkin Lymphoma
University of Cologne 12
Testing effectiveness (Phase 2)Active Not RecruitingNCT04268706
What this trial is testing

Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)

Who this might be right for
Hodgkin Lymphoma, AdultHodgkin Disease RecurrentHodgkin Disease Refractory+1 more
Tessa Therapeutics 97
Early research (Phase 1)Active Not RecruitingNCT05162976
What this trial is testing

CC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or Relapsed

Who this might be right for
Recurrent Classic Hodgkin LymphomaRefractory Classic Hodgkin Lymphoma
City of Hope Medical Center 33
Large-scale testing (Phase 3)Ended earlyNCT02951156
What this trial is testing

Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)

Who this might be right for
Diffuse Large B-Cell Lymphoma
Pfizer 29
Early research (Phase 1)Study completedNCT02665650
What this trial is testing

Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Who this might be right for
Hodgkin Lymphoma
Affimed GmbH 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT05821088
What this trial is testing

Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma

Who this might be right for
Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin LymphomaRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Grade 3b Follicular Lymphoma+19 more
David Bond, MD
Testing effectiveness (Phase 2)Study completedNCT05140382
What this trial is testing

AZD4573 as Monotherapy or in Combinations With Anti-cancer Agents in Patients With r/r PTCL or r/r cHL

Who this might be right for
Relapsed/Refractory Peripheral T-cell LymphomaRelapsed/Refractory Classical Hodgkins Lymphoma
AstraZeneca 52
Testing effectiveness (Phase 2)WithdrawnNCT00298467
What this trial is testing

MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma

Who this might be right for
Lymphoma, Large-Cell
Bristol-Myers Squibb 45
Early research (Phase 1)Study completedNCT01561911
What this trial is testing

A Phase I Study of the Chimeric Anti-CD40 Monoclonal Antibody ChiLob 7/4 to Treat Advanced Malignancies Refractory to Conventional Anti-cancer Treatment

Who this might be right for
CancerNeoplasmsLymphoma+2 more
Cancer Research UK 29
Testing effectiveness (Phase 2)Ended earlyNCT05255601
What this trial is testing

Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma

Who this might be right for
Lymphoma, Non-HodgkinHodgkin Disease
Bristol-Myers Squibb 5
Testing effectiveness (Phase 2)UnknownNCT05896046
What this trial is testing

SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin Lymphoma

Who this might be right for
Relapsed or Refractory Hodgkin Lymphoma
Chinese PLA General Hospital 100
Testing effectiveness (Phase 2)Ended earlyNCT05179603
What this trial is testing

SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205]

Who this might be right for
Classic Hodgkin LymphomaDiffuse Large B-cell Lymphoma
Sanofi 14
Testing effectiveness (Phase 2)Study completedNCT02453594
What this trial is testing

Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087)

Who this might be right for
Hodgkin Lymphoma
Merck Sharp & Dohme LLC 211
Testing effectiveness (Phase 2)Active Not RecruitingNCT03057795
What this trial is testing

Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma

Who this might be right for
Classic Hodgkin LymphomaRecurrent Hodgkin LymphomaRefractory Hodgkin Lymphoma
City of Hope Medical Center 62
Testing effectiveness (Phase 2)Ended earlyNCT04788043
What this trial is testing

Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma

Who this might be right for
Hodgkin LymphomaClassic Hodgkin LymphomaRelapsed Classical Hodgkin Lymphoma+1 more
Ranjana Advani 8
Next Page
37